Table 4.
Combinations of urinary AKI biomarkers and AKI discrimination and prediction at early and late cisplatin visits
| Time Point | Area Under Receiver Operating Characteristic Curve (95% Confidence Interval) | |||
|---|---|---|---|---|
| SCr-AKI Discrimination | SCr-AKI Prediction | SCr+eAKI Discrimination | Severe SCr-AKI Discrimination | |
| Early visit | ||||
| NGAL (pre)+KIM-1 (pre) | 0.54 (0.43 to 0.65) | 0.54 (0.43 to 0.65) | 0.60 (0.48 to 0.73) | 0.65 (0.44 to 0.85) |
| NGAL (post)+KIM-1 (post) | 0.60 (0.49 to 0.71) | 0.55 (0.41 to 0.69) | 0.70 (0.58 to 0.82) | 0.62 (0.41 to 0.83) |
| NGAL (discharge)+KIM-1 (discharge) | 0.64 (0.55 to 0.73) | 0.46 (0.31 to 0.62) | 0.66 (0.54 to 0.77) | 0.60 (0.43 to 0.78) |
| NGAL (pre)+KIM-1 (post) | 0.62 (0.51 to 0.72) | 0.57 (0.43 to 0.71) | 0.71 (0.59 to 0.83) | 0.70 (0.50 to 0.90) |
| NGAL (post)+KIM-1 (pre) | 0.55 (0.43 to 0.66) | 0.47 (0.33 to 0.61) | 0.64 (0.51 to 0.77) | 0.59 (0.36 to 0.82) |
| NGAL (pre)+KIM-1 (discharge) | 0.59 (0.48 to 0.69) | 0.56 (0.37 to 0.75) | 0.61 (0.49 to 0.74) | 0.66 (0.44 to 0.89) |
| NGAL (discharge)+KIM-1 (pre) | 0.56 (0.44 to 0.67) | 0.60 (0.40 to 0.80) | 0.69 (0.57 to 0.81) | 0.65 (0.42 to 0.89) |
| NGAL (post)+KIM-1 (discharge) | 0.63 (0.54 to 0.73) | 0.55 (0.35 to 0.74) | 0.67 (0.55 to 0.78) | 0.60 (0.42 to 0.79) |
| NGAL (discharge)+KIM-1 (post) | 0.62 (0.51 to 0.73) | 0.55 (0.35 to 0.75) | 0.73 (0.62 to 0.84) | 0.67 (0.44 to 0.91) |
| Late visit | ||||
| NGAL (pre)+KIM-1 (pre) | 0.56 (0.40 to 0.71) | 0.56 (0.40 to 0.71) | 0.57 (0.38 to 0.75) | 0.73 (0.50 to 0.96) |
| NGAL (post)+KIM-1 (post) | 0.70 (0.56 to 0.84) | 0.65 (0.46 to 0.83) | 0.65 (0.47 to 0.82) | 0.83 (0.65 to 1.00) |
| NGAL (discharge)+KIM-1 (discharge) | 0.72 (0.58 to 0.86) | 0.94 (0.86 to 1.00) | 0.74 (0.60 to 0.88) | 0.84 (0.72 to 0.97) |
| NGAL (pre)+KIM-1 (post) | 0.62 (0.47 to 0.77) | 0.60 (0.46 to 0.75) | 0.59 (0.42 to 0.76) | 0.80 (0.61 to 1.00) |
| NGAL (post)+KIM-1 (pre) | 0.62 (0.45 to 0.78) | 0.64 (0.48 to 0.80) | 0.58 (0.38 to 0.78) | 0.77 (0.55 to 0.99) |
| NGAL (pre)+KIM-1 (discharge) | 0.75 (0.63 to 0.87) | 0.89 (0.72 to 1.00) | 0.73 (0.59 to 0.87) | 0.86 (0.75 to 0.97) |
| NGAL (discharge)+KIM-1 (pre) | 0.71 (0.54 to 0.89) | 0.96 (0.90 to 1.00) | 0.66 (0.46 to 0.86) | 0.85 (0.72 to 0.98) |
| NGAL (post)+KIM-1 (Discharge) | 0.75 (0.62 to 0.87) | 0.88 (0.68 to 1.00) | 0.72 (0.56 to 0.87) | 0.87 (0.76 to 0.99) |
| NGAL (discharge)+KIM-1 (post) | 0.72 (0.56 to 0.88) | 0.95 (0.88 to 1.00) | 0.70 (0.52 to 0.87) | 0.83 (0.68 to 0.97) |
Combinations of biomarkers were estimated with logistic regression models. Up to two biomarkers were included in each model. SCr-AKI, serum creatinine–defined AKI; SCr+eAKI; composite outcome of SCr-AKI and electrolyte-AKI; NGAL, neutrophil gelatinase-associated lipocalin; pre, preinfusion; KIM-1, kidney injury molecule-1; post, postinfusion; discharge, hospital discharge.